InflaRx (IFRX) News Today $1.26 -0.21 (-14.29%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.87%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period InflaRx Regains Nasdaq Compliance with Share Price Recovery4 hours ago | tipranks.comInflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 12 at 2:10 PM | finanznachrichten.deInflaRx regains compliance with Nasdaq min bid price requirementSeptember 12 at 2:10 PM | msn.comInflaRx N.V. Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 12 at 8:51 AM | quiverquant.comQInflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 12 at 8:30 AM | globenewswire.comEquities Analysts Offer Predictions for InflaRx Q3 EarningsSeptember 6, 2025 | marketbeat.comQ3 Earnings Estimate for InflaRx Issued By HC WainwrightSeptember 6, 2025 | americanbankingnews.comInflaRx (NASDAQ:IFRX) Receives Buy Rating from HC WainwrightSeptember 4, 2025 | marketbeat.com683 Capital Management LLC Raises Stake in InflaRx N.V. $IFRXSeptember 4, 2025 | marketbeat.comHC Wainwright Initiates Coverage on InflaRx (NASDAQ:IFRX)September 4, 2025 | americanbankingnews.comDAFNA Capital Management LLC Takes $459,000 Position in InflaRx N.V. $IFRXSeptember 1, 2025 | marketbeat.comInflaRx Announces Participation in September Investor ConferencesAugust 21, 2025 | markets.businessinsider.comInflaRx Announces Participation in September Investor ConferencesAugust 21, 2025 | globenewswire.comInflaRx Reports Significant Losses in H1 2025 FinancialsAugust 7, 2025 | tipranks.comInflaRx N.V. Announces Upcoming Data Readouts for INF904 in CSU and HS, Financial Results for Q2 2025, and Updates on Vilobelimab and BDB-001 DevelopmentsAugust 7, 2025 | quiverquant.comQInflaRx Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comInflaRx (IFRX) to Release Earnings on ThursdayAugust 2, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Trading 2.8% Higher - What's Next?August 1, 2025 | marketbeat.comInflaRx to Report Second Quarter 2025 Results on August 7, 2025July 31, 2025 | globenewswire.comInflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data ExpectedJuly 25, 2025 | msn.comInflaRx Announces Receipt of Nasdaq Deficiency Notice ... - MorningstarJuly 12, 2025 | morningstar.comMInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum ...July 12, 2025 | seekingalpha.comInflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 12, 2025 | finanznachrichten.deInflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementJuly 11, 2025 | quiverquant.comQInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 11, 2025 | globenewswire.comInflaRx (NASDAQ:IFRX) Shares Up 2.1% - Here's WhyJuly 10, 2025 | marketbeat.comInflaRx N.V. (IFRX) Latest Stock News & Headlines - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comInflaRx Appoints KPMG as New Auditor Following Shareholder ApprovalJune 27, 2025 | tipranks.comInflaRx N.V. (NASDAQ:IFRX) Short Interest UpdateJune 18, 2025 | marketbeat.comBrokers Issue Forecasts for InflaRx FY2026 EarningsJune 10, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Sees Large Decline in Short InterestJune 4, 2025 | marketbeat.comInflaRx stock rating cut, price target slashed to $2 by Raymond JamesMay 30, 2025 | investing.comInflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | BenzingaMay 30, 2025 | benzinga.comOppenheimer Has Lowered Expectations for InflaRx (NASDAQ:IFRX) Stock PriceMay 30, 2025 | marketbeat.comInflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage UncertaintyMay 29, 2025 | tipranks.comInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | finanznachrichten.deInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28, 2025 | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28, 2025 | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28, 2025 | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpMay 28, 2025 | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28, 2025 | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for InflaRx Raised by Cantor FitzgeraldMay 13, 2025 | marketbeat.comQ2 Earnings Forecast for InflaRx Issued By Leerink PartnrsMay 13, 2025 | marketbeat.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comInflaRx Reports Q1 2025 Financial Results with Reduced LossesMay 7, 2025 | tipranks.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼1.060.93▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼62▲IFRX Articles Average Week Get the Latest News and Ratings for IFRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for InflaRx and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Replimune Group News Today Zhengye Biotechnology News Today Prime Medicine News Today Cullinan Therapeutics News Today Kodiak Sciences News Today COMPASS Pathways News Today Prothena News Today iTeos Therapeutics News Today Solid Biosciences News Today MBX Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
